• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Deferasirox-induced serious adverse reaction in a pediatric patient: pharmacokinetic and pharmacogenetic analysis.

作者信息

Marano M, Bottaro G, Goffredo B, Stoppa F, Pisani M, Marinaro A M, Deodato F, Dionisi-Vici C, Clementi E, Falvella F S

机构信息

DEA Intensive Care Unit, IRCCS "Bambino Gesù" Children Hospital, Piazza S. Onofrio 4, Rome, 00165, Italy.

Department of Pediatrics "Tor Vergata University", Rome, Italy.

出版信息

Eur J Clin Pharmacol. 2016 Feb;72(2):247-8. doi: 10.1007/s00228-015-1956-2. Epub 2015 Sep 24.

DOI:10.1007/s00228-015-1956-2
PMID:26403473
Abstract
摘要

相似文献

1
Deferasirox-induced serious adverse reaction in a pediatric patient: pharmacokinetic and pharmacogenetic analysis.地拉罗司在一名儿科患者中引起的严重不良反应：药代动力学和药物遗传学分析。
Eur J Clin Pharmacol. 2016 Feb;72(2):247-8. doi: 10.1007/s00228-015-1956-2. Epub 2015 Sep 24.
2
Pharmacogenetic study of deferasirox, an iron chelating agent.铁螯合剂地拉罗司的药物遗传学研究。
PLoS One. 2013 May 30;8(5):e64114. doi: 10.1371/journal.pone.0064114. Print 2013.
3
Hyperchloremic metabolic acidosis due to deferasirox in a patient with beta thalassemia major.继发于地拉罗司治疗的β-地中海贫血患者的高氯性代谢性酸中毒。
Ann Pharmacother. 2010 Jan;44(1):219-21. doi: 10.1345/aph.1M440. Epub 2009 Nov 24.
4
Influence of single-nucleotide polymorphisms on deferasirox C trough levels and effectiveness.单核苷酸多态性对地拉罗司C谷浓度及疗效的影响。
Pharmacogenomics J. 2015 Jun;15(3):263-71. doi: 10.1038/tpj.2014.65. Epub 2014 Oct 28.
5
Development of lens opacities with peculiar characteristics in patients affected by thalassemia major on chelating treatment with deferasirox (ICL670) at the Pediatric Clinic in Monza, Italy.在意大利蒙扎儿科诊所，接受去铁罗克斯（ICL670）螯合治疗的重型地中海贫血患者出现具有特殊特征的晶状体混浊。
Haematologica. 2008 Jan;93(1):e9-10. doi: 10.3324/haematol.11782.
6
Gastric ulcer in a child treated with deferasirox.使用地拉罗司治疗的儿童胃溃疡。
Pharm World Sci. 2010 Apr;32(2):112-3. doi: 10.1007/s11096-009-9357-1. Epub 2010 Jan 9.
7
Hyperchloraemic metabolic acidosis induced by the iron chelator deferasirox: a case report and review of the literature.铁螯合剂地拉罗司诱导的高氯代谢性酸中毒：病例报告及文献复习。
J Clin Pharm Ther. 2013 Dec;38(6):526-7. doi: 10.1111/jcpt.12095. Epub 2013 Aug 27.
8
Successful desensitization to deferasirox in a paediatric patient with β-Thalassaemia major.一名重型β地中海贫血患儿成功实现对地拉罗司的脱敏治疗。
Pediatr Allergy Immunol. 2017 Mar;28(2):199-201. doi: 10.1111/pai.12677. Epub 2016 Dec 8.
9
Comment to: Development of lens opacities with peculiar characteristics in patients affected by thalassemia major on chelating treatment with deferasirox. Haematologica 2008;93:e9-10.
Haematologica. 2008 Jun;93(6):e49; discussion e50. doi: 10.3324/haematol.12944.
10
Nephrolithiasis in beta thalassemia major patients treated with deferasirox: an advent or an adverse event? A single Greek center experience.接受地拉罗司治疗的重型β地中海贫血患者的肾结石：是偶然现象还是不良事件？希腊单一中心经验
Ann Hematol. 2013 Jan;92(2):263-5. doi: 10.1007/s00277-012-1558-3. Epub 2012 Aug 30.

引用本文的文献

1
Case report: Acute liver failure during deferasirox therapy and the potential role of pharmacogenetics.病例报告：地拉罗司治疗期间的急性肝衰竭及药物遗传学的潜在作用。
Front Pharmacol. 2024 Oct 23;15:1477755. doi: 10.3389/fphar.2024.1477755. eCollection 2024.
2
Deferasirox-induced hyperammonemia and Fanconi syndrome: a case report.地拉罗司诱发的高氨血症和范科尼综合征：一例报告
Front Pediatr. 2024 Oct 10;12:1461867. doi: 10.3389/fped.2024.1461867. eCollection 2024.
3
Manuka combinations with nigella sativa and hydroxyurea in treating iron overload of pediatric β-thalassemia major, randomized clinical trial.

本文引用的文献

1
Efficacy of deferasirox in children with β-thalassemia: single-center 3 year experience.地拉罗司治疗β地中海贫血患儿的疗效：单中心3年经验
Pediatr Int. 2014 Aug;56(4):530-3. doi: 10.1111/ped.12323. Epub 2014 May 30.
2
Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: A quantitative systematic review.UDP-葡萄糖醛酸转移酶多态性与药物剂量相关性：定量系统评价。
Pharmacol Ther. 2014 Jan;141(1):92-116. doi: 10.1016/j.pharmthera.2013.09.002. Epub 2013 Sep 27.
3
Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms.
麦卢卡与黑种草籽及羟基脲联合治疗小儿重型β地中海贫血铁过载的随机临床试验。
Heliyon. 2024 Jun 26;10(13):e33707. doi: 10.1016/j.heliyon.2024.e33707. eCollection 2024 Jul 15.
4
Joining the dots: Answers.连接各个点：答案。
Pediatr Nephrol. 2022 Jul;37(7):1525-1528. doi: 10.1007/s00467-021-05415-y. Epub 2022 Jan 27.
5
Kidney Tubular Damage Secondary to Deferasirox: Systematic Literature Review.地拉罗司继发的肾小管损伤：系统文献综述
Children (Basel). 2021 Dec 1;8(12):1104. doi: 10.3390/children8121104.
6
The Cross-Link between Ferroptosis and Kidney Diseases.铁死亡与肾脏疾病的关联。
Oxid Med Cell Longev. 2021 May 3;2021:6654887. doi: 10.1155/2021/6654887. eCollection 2021.
7
Synthesis and Study of Multifunctional Cyclodextrin-Deferasirox Hybrids.多功能环糊精-地拉罗司杂化物的合成与研究。
ChemMedChem. 2019 Aug 20;14(16):1484-1492. doi: 10.1002/cmdc.201900334. Epub 2019 Jun 24.
8
What is known about deferasirox chelation therapy in pediatric HSCT recipients: two case reports of metabolic acidosis.关于去铁罗昔螯合疗法在儿童造血干细胞移植受者中的情况：两例代谢性酸中毒病例报告。
Ther Clin Risk Manag. 2018 Sep 7;14:1649-1655. doi: 10.2147/TCRM.S170761. eCollection 2018.
9
Significant Hyperbilirubinemia and Acute Hepatocellular Jaundice in a Pediatric Patient Receiving Deferasirox: A Case Report.接受地拉罗司治疗的儿科患者出现显著高胆红素血症和急性肝细胞性黄疸：一例报告
J Pediatr Pharmacol Ther. 2018 Jan-Feb;23(1):64-67. doi: 10.5863/1551-6776-23.1.64.
UGT1A1*28 和/或 UGT1A1*6 多态性的癌症患者中伊立替康的基因型指导剂量发现研究。
Cancer Sci. 2011 Oct;102(10):1868-73. doi: 10.1111/j.1349-7006.2011.02030.x. Epub 2011 Aug 12.
4
Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up.去铁酮治疗成人和儿童重型地中海贫血患者：5 年随访期间的疗效和安全性。
Blood. 2011 Jul 28;118(4):884-93. doi: 10.1182/blood-2010-11-316646. Epub 2011 May 31.
5
Hyperchloremic metabolic acidosis due to deferasirox in a patient with beta thalassemia major.继发于地拉罗司治疗的β-地中海贫血患者的高氯性代谢性酸中毒。
Ann Pharmacother. 2010 Jan;44(1):219-21. doi: 10.1345/aph.1M440. Epub 2009 Nov 24.
6
Pharmacokinetics, distribution, metabolism, and excretion of deferasirox and its iron complex in rats.地拉罗司及其铁络合物在大鼠体内的药代动力学、分布、代谢和排泄
Drug Metab Dispos. 2008 Dec;36(12):2523-38. doi: 10.1124/dmd.108.022962. Epub 2008 Sep 5.
7
Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin.对接受伊立替康和顺铂治疗的非小细胞肺癌患者中预测药代动力学和治疗结果的UGT1A基因多态性的综合分析。
J Clin Oncol. 2006 May 20;24(15):2237-44. doi: 10.1200/JCO.2005.03.0239. Epub 2006 Apr 24.
8
Genetic polymorphisms of ATP-binding cassette transporters ABCB1 and ABCG2: therapeutic implications.ATP结合盒转运蛋白ABCB1和ABCG2的基因多态性：治疗意义
Expert Opin Pharmacother. 2005 Nov;6(14):2455-73. doi: 10.1517/14656566.6.14.2455.
9
A method for estimating the probability of adverse drug reactions.一种估算药物不良反应概率的方法。
Clin Pharmacol Ther. 1981 Aug;30(2):239-45. doi: 10.1038/clpt.1981.154.
10
Renal tubular acidosis.肾小管酸中毒
Pediatr Nephrol. 1990 May;4(3):268-75. doi: 10.1007/BF00857675.